ATS View
한국어

Celltrion KRX:068270KOSPI

셀트리온 · Korean news coverage and regulatory filings, organized.

한국어
Articles, 24h3
Articles, 7 days14
DART filings, 7 days0
Articles tracked14since Sep 11

In Q2 2026, Celltrion reported revenue of ₩1.39tn, up 45.0% year on year, and operating profit of ₩452bn. Celltrion (셀트리온) appeared in 14 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Sep 14 with 6 articles. The most common catalyst was clinical & approvals (1). It was most often mentioned alongside Hanmi Pharm and Samsung Biologics.

Celltrion quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩1.39tn+45.0%₩452bn₩371bn
Q1 2026₩1.14tn+36.0%₩322bn₩350bn
Q4 2025 derived₩1.33tn+25.1%₩475bn₩528bn
Q3 2025₩1.03tn+16.7%₩301bn₩332bn
Q2 2025₩961bn+9.9%₩242bn₩63.3bn
Q1 2025₩842bn+14.2%₩149bn₩108bn
Q4 2024 derived₩1.06tn+178.0%₩196bn₩236bn
Q3 2024₩882bn+31.2%₩208bn₩84.1bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.

Celltrion top stories 2 weeks, by number of outlets

  1. 1
    제약株 브랜드평판 1위 삼성바이오로직스…셀트리온·한미약품 추격
    3 outlets · 3 articlesFirst report Sep 14 06:58 핀포인트뉴스Hanmi PharmSamsung Biologics
  2. 2
    셀트리온 ‘짐펜트라’ 美 공략 속도…240mg 고용량 임상 4상 FDA 제출
    1 outlets · 1 articlesFirst report Sep 15 09:01 중앙이코노미뉴스Regulatory approval
  3. 3
    셀트리온 옴리클로, 스페인 점유율 90%…유럽 판매 확대
    1 outlets · 1 articlesFirst report Sep 11 11:14 파이낸스투데이
  4. 4
    WIN, ‘2026 다양성 우수기업’ 10개사 선정…현대차·LG화학·셀트리온 등 수상
    1 outlets · 1 articlesFirst report Sep 13 10:29 코리아포스트 한글판Hyundai MotorLG Chem
  5. 5
    셀트리온·삼성도 공격 출시…치료비 부담 낮아진다
    1 outlets · 1 articlesFirst report Sep 13 18:45 한국경제
  6. 6
    셀트리온, 제약 부문 다양성 우수기업 수상
    1 outlets · 1 articlesFirst report Sep 14 07:38 메드월드뉴스

Latest Celltrion news Korean headlines